Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
50 results about "Potassium channel blocker" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Potassium channel blockers are agents which interfere with conduction through potassium channels.
Opthalmic compositions for treating ocular hypertension
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP
Methods and compositions for treating mammalian spinal cord injuries
InactiveUS7582680B1Recovery functionBiocideEther/acetal active ingredientsNervous systemPolyethylene glycol
Methods of treating an injured vertebrate spinal cord are described. In one aspect of the invention, a method of treating an injured vertebrate spinal cord includes contacting the spinal cord with a biomembrane fusion agent such as a polyalkylene glycol, especially polyethylene glycol. In alternative embodiments of the invention, methods of treating an injured vertebrate spinal cord include contacting the cord with a biomembrane fusion agent and a potassium channel blocker. Other aspects of the invention include compositions for treating a vertebrate nervous system. A preferred composition includes a biomembrane fusion agent, such as a polyalkylene glycol, and a potassium channel blocker, such as an amino-substituted pyridine.
Owner:PURDUE RES FOUND INC
Ophthalmic Compositions for Treating Ocular Hypertension
This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP
Ophthalmic compositions for treating ocular hypertension
This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME LLC
Isoquinoline compound or salt thereof, medicinal composition, preparation method and application thereof
InactiveCN101619038AHigh activityGood heart selectivityOrganic active ingredientsOrganic chemistryIsoquinolinePotassium ions
The invention discloses an isoquinoline compound or salt thereof shown as a formula I, wherein R1 and R2 are H, -OCH3 and -OCH2Ph or -NHSO2CH3 independently or R1 and R2 are connected into -OCH2O-; R3 is -NO2, -NH2 or -NHSO2CH3; and R4, R5, R6 and R7 are independently H, -OCH3, -NO2, -NH2 or -NHSO2CH3. The invention also discloses a preparation method of the compound, the medicinal composition containing the compound, and application of the compound in preparing medicaments for treating anti-arrhythmia. The isoquinoline compound or salt thereof has the effect of potassium ion channel blocker, and shows effective activity of prolonging effective refractory period and better heart selectivity, so the isoquinoline compound or salt thereof has better anti-arrhythmia activity.
Owner:SHANGHAI INST OF PHARMA IND CO LTD
Use of potassium channel blockers to treat cerebral palsy
InactiveUS20130030025A1Signs improvedSymptoms improvedBiocideNervous disorder3-AminopyridinePotassium
Disclosed herein is the use of aminopyridines, such as 3-aminopyridine, 4-aminopyridine or 3,4-diaminopyridine, in the management and treatment of cerebral palsy patients of all ages.
Owner:ACORDA THERAPEUTICS INC
Ophthalmic compositions for treating ocular hypertension
InactiveUS20060020000A1Organic active ingredientsBiocideElevated intraocular pressureOcular hypertension
This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP
Benzimidazole compound and its preparing method and use in medicine production
The present invention discloses one kind of benzimidazole compound and its prepare and application in producing medicine. The compound has the general expression as shown. The compound is potassium ion channel retardant, has arrhythmia treating activity and no side effect, and may be used in preparing medicine for arrhythmia. The preparation process has facile material and mild reaction condition.
Owner:CHINA PHARM UNIV
Ophthalmic compositions for treating ocular hypertension
Owner:MERCK SHARP & DOHME CORP
Ophthalmic compositions for treating ocular hypertension
InactiveUS7528163B2Organic active ingredientsBiocideElevated intraocular pressureOcular hypertension
This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP
Security device including linearly moving member
This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:艾可品牌美国有限公司
Ophthalmic compositions for treating ocular hypertension
Owner:MERCK SHARP & DOHME CORP
Sulfonamides as potassium channel blockers
Owner:ICAGEN INC
Ophthalmic Compositions for Treating Ocular Hypertension
This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP
Novel maxi-k channel blockers, methods of use and process for making the same
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
Owner:MERCK & CO INC
Ophthalmic compositions for treating ocular hypertension
The present invention relates to compounds of formula I which are potent potassium channel blockers or their preparations for the treatment of glaucoma and other conditions which lead to increased intraocular pressure in patients. The present invention also relates to the use of such compounds to provide neuroprotection of the eye in mammals, especially humans.
Owner:SCHERING AG
Method for treating ocular hypertension
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
Owner:MERCK & CO INC
Maxi-k channel blockers, methods of use and process for making the same
Owner:MERCK SHARP & DOHME CORP
Ophthalmic compositions for treating ocular hypertension
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK & CO INC
Ophthalmic compositions for treating ocular hypertension
This invention relates to potent potassium channel blocker compounds of structural Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP
Diphenylurea Derivatives Useful As Potassium Channel Activators
InactiveUS20070293553A1Reduce deliveryImprove blood-brain barrier permeabilityBiocideNervous disorderUrea derivativesPotassium
The present invention relates to the medical use of a certain group of diphenyl urea derivatives as potassium channel blockers for treating cardiovascular diseases, an obstructive or inflammatory airway disease, urinary incontinence, psychosis, epilepsy or pain, or for facilitating the blood-brain barrier permeability for other therapeutic substances. In other aspects the invention relates to the use of these compounds in a method of therapy.
Owner:NEUROSEARCH AS
Ophthalmic Compositions for Treating Ocular Hypertension
InactiveUS20090281154A1Elevated intraocular pressureBiocideOrganic active ingredientsHigh pressureOcular hypertension
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP
Ophthalmic compositions for treating ocular hypertension
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP
Novel maxi-k channel blockers, methods of use and process for making the same
InactiveUS20050239863A1Elevated intraocular pressureBiocideSenses disorderIntra ocular pressureElevated intraocular pressure
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP
Ophthalmic compositions for treating ocular hypertension
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP
Ophthalmic Compositions For Treating Ocular Hypertension
This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP
Ophthalmic compositions for treating ocular hypertension
This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK & CO INC
Ophthalmic compositions for treating ocular hypertension
This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP
Ophthalmic compositions for treating ocular hypertension
Owner:MERCK SHARP & DOHME LLC
Ophthalmic compositions for treating ocular hypertension
Owner:MERCK SHARP & DOHME CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com